0NIR Stock Overview
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €282.10 |
| 52 Week High | €383.50 |
| 52 Week Low | €215.20 |
| Beta | 0.84 |
| 1 Month Change | -23.77% |
| 3 Month Change | -14.30% |
| 1 Year Change | -18.92% |
| 3 Year Change | -39.39% |
| 5 Year Change | 73.49% |
| Change since IPO | 5,641.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NIR | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 1.2% | -1.1% | 2.2% |
| 1Y | -18.9% | -46.8% | 0.9% |
Return vs Industry: 0NIR exceeded the UK Life Sciences industry which returned -41.7% over the past year.
Return vs Market: 0NIR underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| 0NIR volatility | |
|---|---|
| 0NIR Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0NIR's share price has been volatile over the past 3 months.
Volatility Over Time: 0NIR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 14,614 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products.
Sartorius Aktiengesellschaft Fundamentals Summary
| 0NIR fundamental statistics | |
|---|---|
| Market cap | €17.31b |
| Earnings (TTM) | €148.80m |
| Revenue (TTM) | €3.31b |
130.9x
P/E Ratio5.9x
P/S RatioIs 0NIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NIR income statement (TTM) | |
|---|---|
| Revenue | €3.31b |
| Cost of Revenue | €1.80b |
| Gross Profit | €1.51b |
| Other Expenses | €1.36b |
| Earnings | €148.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 19, 2024
| Earnings per share (EPS) | 2.16 |
| Gross Margin | 45.55% |
| Net Profit Margin | 4.49% |
| Debt/Equity Ratio | 134.4% |
How did 0NIR perform over the long term?
See historical performance and comparison